KB-1244

Durvalumab

Home » Antibody » Durvalumab

Background

Durvalumab is a monoclonal antibody of human IgG with a high affinity/selectivity to inhibit PD-L1 binding to PD-1 and CD 80 (but not with PD-L2). Therefore risk related to adverse effects due to PD-L2 inhibition is minimized. An open-label, dose-escalation phase I/II study investigated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of durvalumab monotherapy in NSCLC and urothelial cancer .

Specifications

Catalog Number:
KB-1244
Cell Line Name:
Durvalumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
PDL1
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Keizer RJ, Huitema AD, Schellens JH, Beijnen JH: Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010 Aug;49(8):493-507. 2.Botticella A, Mezquita L, Le Pechoux C, Planchard D: Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619885530.
Please enable JavaScript in your browser to complete this form.